Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
troxerutin + cerebroprotein
- Development stage
- Unknown
- Lead developer
- Harbin Yuheng Pharmaceutical
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Troxerutin + cerebroprotein is a combination therapeutic injection primarily utilized in China for the treatment of cerebrovascular disorders and traumatic brain injuries. The product combines troxerutin, a flavonoid derivative with vasoprotective and antioxidant properties, with cerebroprotein hydrolysate, a mixture of peptides and amino acids derived from animal brain tissue. Troxerutin functions by reducing capillary permeability, inhibiting platelet aggregation, and improving microcirculation. Cerebroprotein hydrolysate provides neurotrophic support, promoting neuronal survival, metabolism, and repair by mimicking the effects of endogenous neurotrophic factors. This synergistic combination is indicated for conditions such as ischemic stroke, sequelae of cerebral hemorrhage, and cognitive dysfunction following brain trauma.
- Brand names
- Qu Ke Lu Ding Nao Dan Bai Shui Jie Wu Zhu She Ye
- Other names
- Troxerutin and Cerebroprotein Hydrolysate InjectionTroxerutin and Cerebroprotein Injection
02
Targets
NTRK2 (Tropomyosin-related kinase receptor type B)HYAL (Hyaluronidase family (HYAL))NTRK1 (Tropomyosin-related receptor kinase A)
Beyond the preview
Go deeper on troxerutin + cerebroprotein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on troxerutin + cerebroprotein.